China Biologic Named to Forbes Magazine's Fifth Annual List of Asia's '200 Best Under a Billion'
October 21 2009 - 8:00AM
PR Newswire (US)
TAI'AN CITY, China, Oct. 21 /PRNewswire-Asia-FirstCall/ -- China
Biologic Products, Inc. (OTC:CBPO) (BULLETIN BOARD: CBPO) ("China
Biologic," or the "Company"), one of the leading plasma-based
pharmaceutical companies in China, today announced that the Company
was named on Forbes Magazine's fifth annual list of Asia's "200
Best Under a Billion" for the year 2009. To assemble its Best Under
a Billion for the Asia-Pacific region, Forbes considered only
listed entities with under $1 billion in sales that have posted
solid top and bottom-line gains and appear to be headed for more.
The 200 Asia-Pacific companies were selected based on their:
profitability, growth, modest indebtedness and future prospects
this year (for a more precise methodology, go online to
http://www.forbes.com/BUB ). According to Forbes, this year's
selection were survivors of unprecedented dislocations in the
global economy over the past 12 months, disrupted supply chains,
frozen lines of credit, depleted consumer coffers and business
spending hibernation, who seized opportunities rising from the
economic uncertainty. China Biologic was one of only 78 companies
in China and Hong Kong to make the prestigious list. "We are
pleased that Forbes Magazine has recognized China Biologic as one
of the Asia-Pacific region's best small and mid-sized companies,"
said Mr. Chao Ming Zhao, the Company's Chief Executive Officer. "We
believe that this accolade reflects our strong financial
performance as well as our position as the leading non-state owned,
plasma-based biopharmaceutical company in China." About China
Biologic Products, Inc. China Biologic Products, Inc., through its
indirect majority-owned subsidiaries, Shandong Taibang Biological
Products Co. Ltd. and Chongqing Dalin Biologic Technologies Co.,
Ltd, and its equity investment in Xi'an Huitian Blood Products Co.,
Ltd., is currently the largest non-state-owned plasma-based
biopharmaceutical company in China. The Company is a fully
integrated biologic products company with plasma collection,
production and manufacturing, research and development, and
commercial operations. The Company's plasma-based biopharmaceutical
products are irreplaceable during medical emergencies, and are used
for the prevention and treatment of various diseases. The Company
sells its products to hospitals and other healthcare facilities in
China. For more information please visit the Company's website
http://www.chinabiologic.com/ Safe Harbor Statement This release
may contain certain "forward-looking statements" relating to the
business of China Biologic Products, Inc. and its subsidiary
companies. All statements, other than statements of historical fact
included herein are "forward-looking statements," including
statements regarding: the significance of the Company's recognition
on Forbes Magazine's list of "Asia's 200 Best Under a Billion" for
the year 2009; the ability of the Company to achieve its commercial
objectives; the business strategy, plans and objectives of the
Company and its subsidiaries; and any other statements of
non-historical information. These forward-looking statements are
often identified by the use of forward-looking terminology such as
"believes," "expects" or similar expressions, and involve known and
unknown risks and uncertainties. Although the Company believes that
the expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. Investors should
not place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of
factors, including those discussed in the Company's periodic
reports that are filed with the Securities and Exchange Commission
and available on its website (http://www.sec.gov/ ). All forward-
looking statements attributable to the Company or persons acting on
its behalf are expressly qualified in their entirety by these
factors. Other than as required under the securities laws, the
Company does not assume a duty to update these forward-looking
statements. For more information, please contact: Company Contact:
Mr. Y. Tristan Kuo Chief Financial Officer China Biologic Products,
Inc. Tel: +86-538-6202206 Email: Web: http://www.chinabiologic.com/
Investor Relations Contact: Mr. Crocker Coulson, President CCG
Investor Relations Tel: +1-646-213-1915 (NY office) Email: Web:
http://www.ccgir.com/ DATASOURCE: China Biologic Products, Inc.
CONTACT: Mr. Y. Tristan Kuo, Chief Financial Officer of China
Biologic Products, Inc., +86-538-6202206, ; or Investors, Crocker
Coulson, President of CCG Investor Relations, +1-646-213-1915, ,
for China Biologic Products, Inc. Web site:
http://www.forbes.com/BUB http://www.chinabiologic.com/
http://www.ccgir.com/
Copyright